When.com Web Search

  1. Ads

    related to: parkinson's carbidopa levodopa side effects

Search results

  1. Results From The WOW.Com Content Network
  2. Carbidopa/levodopa - Wikipedia

    en.wikipedia.org/wiki/Carbidopa/levodopa

    Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. [6] It is primarily used to manage the symptoms of Parkinson's disease , but it does not slow down the disease or stop it from getting worse. [ 6 ]

  3. Carbidopa - Wikipedia

    en.wikipedia.org/wiki/Carbidopa

    Carbidopa (Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa.This property is significant in that it allows a greater proportion of administered levodopa to cross the blood–brain barrier for central nervous system effect, instead of being peripherally metabolised into substances unable to cross said barrier.

  4. Carbidopa/levodopa/entacapone - Wikipedia

    en.wikipedia.org/wiki/Carbidopa/levodopa/entacapone

    2 Side effects. 3 Drug ... Carbidopa/levodopa ... In the European Union it is indicated for the treatment of adults with Parkinson's disease and end-of-dose motor ...

  5. Management of Parkinson's disease - Wikipedia

    en.wikipedia.org/wiki/Management_of_Parkinson's...

    Selegiline is used to help control the symptoms of Parkinson's disease in people who are taking levodopa and carbidopa combination (Sinemet). Selegiline may help people with PD by stopping the effects of levodopa/carbidopa from wearing off, and increasing the length of time levodopa/carbidopa continues to control symptoms.

  6. Aromatic L-amino acid decarboxylase inhibitor - Wikipedia

    en.wikipedia.org/wiki/Aromatic_L-amino_acid_de...

    Peripherally selective DDCIs incapable of crossing the protective blood–brain barrier (BBB) are used in augmentation of L-DOPA (levodopa) in the treatment of Parkinson's disease (PD) to block the conversion of L-DOPA into dopamine outside the brain, for the purpose of reducing adverse side effects. [3]

  7. FDA Issues Complete Response Letter for RYTARY™ (Carbidopa ...

    www.aol.com/news/2013-01-21-fda-issues-complete...

    RYTARYis an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson's disease. It is not approved or licensed anywhere in the world.

  1. Ads

    related to: parkinson's carbidopa levodopa side effects